273 related articles for article (PubMed ID: 31875587)
1. Progress on drug pricing negotiations in China.
Tang M; Song P; He J
Biosci Trends; 2020 Jan; 13(6):464-468. PubMed ID: 31875587
[TBL] [Abstract][Full Text] [Related]
2. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
3. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
4. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
[TBL] [Abstract][Full Text] [Related]
5. Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions.
Li H; Liu GG; Wu J; Wu JH; Dong CH; Hu SL
Value Health Reg Issues; 2018 May; 15():133-137. PubMed ID: 29705645
[TBL] [Abstract][Full Text] [Related]
6. Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
Huang C; Ung COL; Wushouer H; Bai L; Huang T; Li X; Guan X; Shi L
Health Res Policy Syst; 2022 Jan; 20(1):3. PubMed ID: 34980159
[TBL] [Abstract][Full Text] [Related]
7. Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis.
Huang C; Ung COL; Wushouer H; Bai L; Li X; Guan X; Shi L
Int J Health Policy Manag; 2022 Aug; 11(8):1489-1495. PubMed ID: 34273922
[TBL] [Abstract][Full Text] [Related]
8. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
Villa F; Tutone M; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G; Jommi C
Health Policy; 2019 Jun; 123(6):595-600. PubMed ID: 31097207
[TBL] [Abstract][Full Text] [Related]
9. Consistency of new drug pricing in Korea: Bridging variations among personnel in price negotiations.
Kwon HY; Kim J
Health Policy; 2020 Sep; 124(9):965-970. PubMed ID: 32660816
[TBL] [Abstract][Full Text] [Related]
10. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.
Liu Y; Yi H; Fang K; Bao Y; Li X
Front Public Health; 2022; 10():942638. PubMed ID: 35937254
[TBL] [Abstract][Full Text] [Related]
11. The correlation between the costs and clinical benefits of national price-negotiated anticancer drugs for specific cancers in China.
Bao Y; Liu Y; Ma R; Zhang P; Li X
J Glob Health; 2023 Nov; 13():04140. PubMed ID: 37934965
[TBL] [Abstract][Full Text] [Related]
12. A new entity for the negotiation of public procurement prices for patented medicines in Mexico.
Gómez-Dantés O; Wirtz VJ; Reich MR; Terrazas P; Ortiz M
Bull World Health Organ; 2012 Oct; 90(10):788-92. PubMed ID: 23109747
[TBL] [Abstract][Full Text] [Related]
13. The reimbursement decision speed for oncology new drugs in China and its determinant factors.
Zhu X; Chen Y
Front Public Health; 2023; 11():1207739. PubMed ID: 38026304
[TBL] [Abstract][Full Text] [Related]
14. The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.
Li BX; Wang YQ; Yi YY; Zhou N; Lv ZX; Ma R; Li X; Yuan N
BMC Public Health; 2024 May; 24(1):1309. PubMed ID: 38745323
[TBL] [Abstract][Full Text] [Related]
15. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
Gleeson D; Lopert R; Reid P
Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
[TBL] [Abstract][Full Text] [Related]
16. Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.
Husereau D; Dempster W; Blanchard A; Chambers J
Value Health; 2014 Dec; 17(8):888-94. PubMed ID: 25498784
[TBL] [Abstract][Full Text] [Related]
17. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
[TBL] [Abstract][Full Text] [Related]
18. Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals.
Main B; Csanadi M; Ozieranski P
Health Econ Policy Law; 2022 Jul; 17(3):348-365. PubMed ID: 35382921
[TBL] [Abstract][Full Text] [Related]
19. From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy.
Rossini EE; Galeone C; Lucchetti C; Jommi C
Pharmacoecon Open; 2024 Mar; 8(2):251-261. PubMed ID: 38228997
[TBL] [Abstract][Full Text] [Related]
20. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
Rong X; Yin J; Duan S; Sun Q; Babar ZU
BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]